2 edition of Epstein-Barr virus-specific cytotoxic T lymphocyte responses in Hodgkin"s disease found in the catalog.
WESTMINSTER REVIEW, V.123-128
A collection of decrees by the Court of Exchequer in tithe-causes
Technology, philosophical and social aspects
Removing certain restrictions on land acquisitions for Antietam Battlefield
political and economic role of the military in the Chinese Communist movement, 1927-1959
Theatrical biography; or, Memoirs of the principle performers of the three Theatres Royal
Residential energy demand models
Mr. T. W. Anthony Woo
English dictionary, explaining the difficult terms that are used in divinity, husbandry, physick, philosophy, law, navigation, mathematicks, and other arts and sciences... Together with the etymological derivation of them from their proper fountains, whether Hebrew, Greek, Latin, French, or any other language.
Costals & the hippogriff.
Epstein-Barr virus-specific cytotoxic T lymphocyte responses in the blood and tumor site of Hodgkin's disease patients: implications for a T-cell-based therapy.
Chapman AL(1), Rickinson AB, Thomas WA, Jarrett RF, Crocker J, Lee by: Epstein-Barr Virus-specific Cytotoxic T Lymphocyte Responses in the Blood and Tumor Site of Hodgkin’s Disease Patients Implications for a T-cell-based Therapy.
Adoptive transfer of Epstein Barr virus (EBV)-specific cytotoxic T-lymphocytes (EBV-CTLs) has shown that these cells persist in patients with EBV(+) Hodgkin lymphoma (HD) to produce complete tumor responses.
Treatment failure, however, occurs if a subpopulation of malignant cells in the tumor lacks or loses expression of EBV by: Epstein-Barr Virus-specific Cytotoxic T Lymphocyte Responses in the Blood and Tumor Site of Hodgkin’s Disease Patients Implications for a T-cell-based Therapy Ann L.
Chapman, Alan B. Rickinson, Wendy A. Thomas, Ruth F. Jarrett, John Crocker and Cited by: Epstein Barr virus (EBV)+ Hodgkin's disease (HD) expresses clearly identified tumor antigens derived from the virus and could, in principle, be a target for adoptive immunotherapy with viral antigen-specific T cells.
Epstein Barr virus (EBV) + Hodgkin's disease (HD) expresses clearly identified tumor antigens derived from the virus and could, in principle, be a target for adoptive immunotherapy with viral antigen–specific T cells.
Epstein – Barr virus specific cytotoxic T lymphocytes for the treatment of severe epstein‐barr virus mucocutaneous ulcer the diagnosis of EBV MCU was established based on the extra‐nodal location of disease, mucosal ulceration, and lack of progression over 3 months.
(3 allele and restricted through a shared HLA allele) allogeneic. Abstract Adoptive transfer of Epstein Barr virus (EBV)–specific cytotoxic T-lymphocytes (EBV-CTLs) has shown that these cells persist in patients with EBV+Hodgkin lymphoma (HD) to produce complete tumor responses.
Treatment failure, however, occurs if a subpopulation of malignant cells in the tumor lacks or loses expression of EBV antigens. Abstract. Epstein-Barr virus (EBV) is a ubiquitous human herpesvirus which causes acute infectious mononucleosis and is etiologically associated with malignant lymphoproliferative disorders including Burkitt\u27s lymphoma, nasopharyngeal carcinoma, B-cell lymphomas in immunocompromised hosts, Hodgkin\u27s disease, T cell lymphomas, and smooth muscle tumors in allograft recipients.
Epstein Barr virus (EBV) is the most common human tumor virus, persistently infecting more than 95% of the human adult population and readily transforming human B cell in culture. Fortunately, only a small minority of EBV carriers develops virus associated malignancies. The majority controls persistent EBV infection with cytotoxic lymphocytes, mainly NK, γδ and CD8 + T cells and the characteristics of the required immune responses.
To determine the feasibility of generating EBV specific cytotoxic T cell lines from patients with active EBV positive Lymphoma including Hodgkin Disease (HD) or Non-Hodgkin Lymphoma (NHL).
[ Time Frame: 6 weeks ] To determine the survival, immunological efficacy and anti-tumor effects of EBV specific cytotoxic T-lymphocyte lines. Adoptive immunotherapy with allogeneic, Epstein–Barr virus (EBV)‐specific cytotoxic T‐lymphocytes (CTL) for patients with recurrent, refractory, EBV‐positive Hodgkin disease was safe and resulted in.
Abstract A subset of Hodgkin's disease (HD) patients have detectable Epstein-Barr virus (EBV) genomes in the malignant Reed-Sternberg (R-S) cells. R-S cells express only a limited set of latent EBV proteins, but only LMP1 and LMP2 can potentially elicit a CD8 + cytotoxic T-lymphocyte (CTL) response.
The Epstein-Barr virus (EBV) is associated with the development of several human tumors, including Hodgkin's lymphoma (HL) and EBV-positive undifferentiated nasopharyngeal carcinoma (NPC).1 In HL, the malignant Hodgkin's and Reed-Sternberg (HRS) cells constitute only a minority of the total tumor mass, and are surrounded by variable proportions of nonmalignant reactive cells.
To evaluate the safety of escalating doses of autologous Epstein-Barr Virus (EBV)-specific cytotoxic T-lymphocytes (CTLs), genetically modified to express an artificial T-cell receptor (CAR) targeting the cluster of differentiation (CD)30 molecule (30), in patients with CD30+ refractory/relapsed Hodgkin lymphoma (HL) or non-Hodgkin lymphoma (NHL).
Epstein‐Barr virus (EBV) is associated with several human malignancies that each show different viral gene expression profiles. In malignancies such as Hodgkin's disease and nasopharyngeal carcinoma only Epstein‐Barr nuclear antigen 1 (EBNA1) and varying levels of latent membrane proteins 1 and 2 (LMP1 and ‐2) are expressed.
Epstein–Barr virus-specific cytotoxic T lymphocyte responses in the blood and tumor site of Hodgkin's disease patients: implications for a T. Epstein–Barr virus (EBV) expression was investigated by immunohistochemistry (latent membrane protein 1 [LMP-1]) and in situ hybridization (EBV encoded RNA [EBER]) in biopsies from 95 patients.
Purpose Tumor cells from approximately 40% of patients with Hodgkin or non-Hodgkin lymphoma express the type II latency Epstein-Barr virus (EBV) antigens latent membrane protein 1 (LMP1) and LMP2, which represent attractive targets for immunotherapy.
Because T cells specific for these antigens are present with low frequency and may be rendered anergic by the tumors that. Epstein-Barr virus-specific cytotoxic T lymphocyte responses in the blood and tumor site of Hodgkin's disease patients: implications for a T-cell-based therapy.
Chapman AL, Rickinson AB, Thomas WA, Jarrett RF, Crocker J, Lee SP. Cancer Res, 61(16), 01 Aug Cited by 55 articles | PMID:.
Epstein‐Barr virus‐ (EBV) related DNA and RNA can be found in tissues involved with Hodgkin's disease, specifically in the Reed‐Sternberg cells. These cells also express the membrane antigens LMP1 and LMP 2A and 2B.(e) Impaired CD4 + responses are thought to be responsible for the EBV-induced infectious mononucleosis seen in X-linked lymphoproliferative disease patients who have a mutation or deletion in signalling lymphocyte activation molecule (SLAM)-associated protein (SAP), an inhibitor of the T cell costimulatory molecule SLAM or CDw Epstein‐Barr virus–positive (EBV‐positive) diffuse large B‐cell lymphoma (DLBCL) of the elderly is a newly described lymphoproliferative disorder recently included as a “provisional” entity in the most current WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues.